Zepbound denials have become more common as plans tighten the rules around GLP-1 medications, but a denial is the start of a process, not the end of it. A well-documented appeal, built around medical necessity, resolves many of them. Here is how to put one together.
Why Zepbound claims get denied
Prior authorization is now nearly universal for these drugs. Among Medicare Part D plans, prior-authorization requirements for GLP-1 receptor agonists rose from roughly 2.8 to 5% of beneficiaries in 2023 to essentially all of them by 2025. Commercial plans followed the same path. On top of that, many large employers layer step therapy or a required lifestyle program: in 2025, about 34% of firms that cover a GLP-1 for weight loss required a lifestyle or wellness program first.
So most Zepbound denials come down to one of a few things: the prior authorization was missing or incomplete, the plan wants a cheaper step first, the dose or quantity fell outside a limit, or the plan does not cover weight-loss medication at all. The denial letter names which one.
What a strong Zepbound appeal includes
A medical-necessity case is the core of the appeal. Your prescriber documents why tirzepatide is appropriate for you specifically: your BMI, any weight-related conditions such as hypertension, sleep apnea, or prediabetes, and a record of previous weight-management attempts and their outcomes. The goal is to show a reviewer that you meet the plan's own written criteria, point by point.
Ask the plan for those criteria in writing if you do not already have them. Appeals succeed when they answer the exact objection, not a general one.
Use a free appeal-letter template
You do not need to write the letter from scratch. Our free appeal-letter template is ungated, with no email wall, and you can copy it or download the PDF. It lays out the structure a reviewer expects, including the reason for the denial, the medical-necessity points, and the documentation you are enclosing. Pair it with the full appeal walkthrough for the order of operations.
Step therapy and prior-authorization overrides
If the denial is a step-therapy requirement, you can request an exception rather than starting over. Document what you have already tried, with dates and results, and have your prescriber note any medical reason a required drug is unsuitable for you. That override request goes into the appeal alongside your records.
If the internal appeal fails
If your plan denies the internal appeal, you can usually request an external review by an independent reviewer, and your plan must tell you how and by when. If coverage still is not possible, cash-pay is often faster than a prolonged fight. Zepbound is sold to self-pay patients through LillyDirect, and compounded tirzepatide is available through licensed telehealth. We line up the cash-pay options after a denial so you can compare them honestly.
If you are on Medicare, note that the separate Medicare GLP-1 Bridge program covers the Zepbound KwikPen at about $50 per month from July 1, 2026 through December 31, 2027, with a prescriber-submitted prior authorization. That is a specific demonstration program and is processed separately from standard Part D, which still excludes weight-loss drugs.
Sources: Klebanoff et al., JAMA (Sep 2025) on Part D prior-authorization trends; KFF 2025 Employer Health Benefits Survey; CMS Medicare GLP-1 Bridge fact sheet. Rules and prices move quickly, so confirm current details with your plan and your denial letter.